Global Active Pharmaceutical Ingredients CDMO Market by Product (Highly Potent API, Antibody Drug Conjugate) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Active Pharmaceutical Ingredients CDMO Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Active Pharmaceutical Ingredients CDMO Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Active Pharmaceutical Ingredients CDMO Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Active Pharmaceutical Ingredients CDMO Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Active Pharmaceutical Ingredients CDMO Market Size & Forecast, 2018-2028
4.5.1 Active Pharmaceutical Ingredients CDMO Market Size and Y-o-Y Growth
4.5.2 Active Pharmaceutical Ingredients CDMO Market Absolute $ Opportunity
Chapter 5 Global Active Pharmaceutical Ingredients CDMO Market Analysis and Forecast by Product
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Product
5.1.2 Basis Point Share (BPS) Analysis by Product
5.1.3 Absolute $ Opportunity Assessment by Product
5.2 Active Pharmaceutical Ingredients CDMO Market Size Forecast by Product
5.2.1 Highly Potent API
5.2.2 Antibody Drug Conjugate
5.3 Market Attractiveness Analysis by Product
Chapter 6 Global Active Pharmaceutical Ingredients CDMO Market Analysis and Forecast by Region
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Region
6.1.2 Basis Point Share (BPS) Analysis by Region
6.1.3 Absolute $ Opportunity Assessment by Region
6.2 Active Pharmaceutical Ingredients CDMO Market Size Forecast by Region
6.2.1 North America
6.2.2 Europe
6.2.3 Asia Pacific
6.2.4 Latin America
6.2.5 Middle East & Africa (MEA)
6.3 Market Attractiveness Analysis by Region
Chapter 7 Coronavirus Disease (COVID-19) Impact
7.1 Introduction
7.2 Current & Future Impact Analysis
7.3 Economic Impact Analysis
7.4 Government Policies
7.5 Investment Scenario
Chapter 8 North America Active Pharmaceutical Ingredients CDMO Analysis and Forecast
8.1 Introduction
8.2 North America Active Pharmaceutical Ingredients CDMO Market Size Forecast by Country
8.2.1 U.S.
8.2.2 Canada
8.3 Basis Point Share (BPS) Analysis by Country
8.4 Absolute $ Opportunity Assessment by Country
8.5 Market Attractiveness Analysis by Country
8.6 North America Active Pharmaceutical Ingredients CDMO Market Size Forecast by Product
8.6.1 Highly Potent API
8.6.2 Antibody Drug Conjugate
8.7 Basis Point Share (BPS) Analysis by Product
8.8 Absolute $ Opportunity Assessment by Product
8.9 Market Attractiveness Analysis by Product
Chapter 9 Europe Active Pharmaceutical Ingredients CDMO Analysis and Forecast
9.1 Introduction
9.2 Europe Active Pharmaceutical Ingredients CDMO Market Size Forecast by Country
9.2.1 Germany
9.2.2 France
9.2.3 Italy
9.2.4 U.K.
9.2.5 Spain
9.2.6 Russia
9.2.7 Rest of Europe
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 Europe Active Pharmaceutical Ingredients CDMO Market Size Forecast by Product
9.6.1 Highly Potent API
9.6.2 Antibody Drug Conjugate
9.7 Basis Point Share (BPS) Analysis by Product
9.8 Absolute $ Opportunity Assessment by Product
9.9 Market Attractiveness Analysis by Product
Chapter 10 Asia Pacific Active Pharmaceutical Ingredients CDMO Analysis and Forecast
10.1 Introduction
10.2 Asia Pacific Active Pharmaceutical Ingredients CDMO Market Size Forecast by Country
10.2.1 China
10.2.2 Japan
10.2.3 South Korea
10.2.4 India
10.2.5 Australia
10.2.6 South East Asia (SEA)
10.2.7 Rest of Asia Pacific (APAC)
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Asia Pacific Active Pharmaceutical Ingredients CDMO Market Size Forecast by Product
10.6.1 Highly Potent API
10.6.2 Antibody Drug Conjugate
10.7 Basis Point Share (BPS) Analysis by Product
10.8 Absolute $ Opportunity Assessment by Product
10.9 Market Attractiveness Analysis by Product
Chapter 11 Latin America Active Pharmaceutical Ingredients CDMO Analysis and Forecast
11.1 Introduction
11.2 Latin America Active Pharmaceutical Ingredients CDMO Market Size Forecast by Country
11.2.1 Brazil
11.2.2 Mexico
11.2.3 Rest of Latin America (LATAM)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Latin America Active Pharmaceutical Ingredients CDMO Market Size Forecast by Product
11.6.1 Highly Potent API
11.6.2 Antibody Drug Conjugate
11.7 Basis Point Share (BPS) Analysis by Product
11.8 Absolute $ Opportunity Assessment by Product
11.9 Market Attractiveness Analysis by Product
Chapter 12 Middle East & Africa (MEA) Active Pharmaceutical Ingredients CDMO Analysis and Forecast
12.1 Introduction
12.2 Middle East & Africa (MEA) Active Pharmaceutical Ingredients CDMO Market Size Forecast by Country
12.2.1 Saudi Arabia
12.2.2 South Africa
12.2.3 UAE
12.2.4 Rest of Middle East & Africa (MEA)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Middle East & Africa (MEA) Active Pharmaceutical Ingredients CDMO Market Size Forecast by Product
12.6.1 Highly Potent API
12.6.2 Antibody Drug Conjugate
12.7 Basis Point Share (BPS) Analysis by Product
12.8 Absolute $ Opportunity Assessment by Product
12.9 Market Attractiveness Analysis by Product
Chapter 13 Competition Landscape
13.1 Active Pharmaceutical Ingredients CDMO Market: Competitive Dashboard
13.2 Global Active Pharmaceutical Ingredients CDMO Market: Market Share Analysis, 2019
13.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
13.3.1 Recipharm
13.3.2 Corden Pharma
13.3.3 Catalent
13.3.4 Lonza
13.3.5 Piramal Pharma Solutions
13.3.6 Boehringer Ingelheim
13.3.7 Samsung Biologics
13.3.8 Thermo Fisher Pantheon
13.3.9 Cambrex
13.3.10 Siegfried